# Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Source: https://onco.cc/trials/nct05771480/  
OnCo record `nct05771480` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Durvalumab, Gemcitabine, Gemcitabine + cisplatin, Oxaliplatin, Carboplatin and Cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) is a phase 3 interventional study registered as NCT05771480 by AstraZeneca, with 142 participants enrolled, started 2023-08-16 and due to reach its primary completion in 2025-10-02. Interventions recorded: Durvalumab, Gemcitabine monotherapy, Gemcitabine + cisplatin, Gemcitabine + oxaliplatin, Gemcitabine + carboplatin and Gemcitabine + cisplatin + S-1.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05771480
- Phase: 3
- Setting: A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE)
- Sponsor: AstraZeneca
- Enrolled: 142

## Sources

- ClinicalTrials.gov NCT05771480: https://clinicaltrials.gov/study/NCT05771480

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05771480.json